Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker AUPH · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupu… NCT07611214 · Lupus Nephritis LUPKYNIS, belimumab, obinutuzumab or anifrolumab | AUPH Aurinia Pharmaceuticals Inc. | Phase 4 | Recruiting | 150 | Mar 2, 2029 | Registry ↗ |
| Aug 3, 2026 | Study of Aritinercept in Patients With Generalized Myasthenia Gravis NCT07596901 · Myasthenia Gravis, Generalized Aritinercept, Placebo | AUPH Aurinia Pharmaceuticals Inc. | Phase 1/2 | Recruiting | 81 | Mar 2, 2029 | Registry ↗ |
| Feb 10, 2026 | Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis NCT05962788 · Adolescent Lupus Nephritis, Pediatric Lupus Nephritis voclosporin | AUPH Aurinia Pharmaceuticals Inc. | Phase 3 | Terminated | 4 | Jul 4, 2025 | Registry ↗ |
| Feb 10, 2026 | Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis NCT05288855 · Adolescent Lupus Nephritis, Pediatric Lupus Nephritis Voclosporin, Placebo Oral Capsule | AUPH Aurinia Pharmaceuticals Inc. | Phase 3 | Terminated | 9 | Jul 3, 2025 | Registry ↗ |
| Jun 24, 2025 | A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the US NCT05337124 · Lupus Nephritis LUPKYNIS | AUPH Aurinia Pharmaceuticals Inc. | — | Completed | 229 | Jan 31, 2025 | Registry ↗ |
| Mar 27, 2023 | Aurinia Renal Response in Active Lupus With Voclosporin NCT03021499 · Lupus Nephritis Voclosporin, Placebo Oral Capsule | AUPH Aurinia Pharmaceuticals Inc. | Phase 3 | Completed | 358 | Sep 24, 2019 | Registry ↗ |
| Mar 27, 2023 | Randomized Placebo-controlled Study of ISA247 in Plaque Psoriasis NCT00244842 · Psoriasis voclosporin, Placebo | AUPH Aurinia Pharmaceuticals Inc. | Phase 3 | Completed | 451 | Oct 2005 | Registry ↗ |
| Dec 14, 2022 | Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin NCT03597464 · Lupus Nephritis Voclosporin, Placebo Oral Capsule | AUPH Aurinia Pharmaceuticals Inc. | Phase 3 | Completed | 216 | Oct 7, 2021 | Registry ↗ |
| Apr 20, 2022 | Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin NCT05306379 · Drug-drug Interaction Simvastatin, Voclosporin | AUPH Aurinia Pharmaceuticals Inc. | Phase 1 | Completed | 24 | Apr 5, 2022 | Registry ↗ |
| Dec 10, 2021 | Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects… NCT04147650 · Dry Eye Syndrome, Keratoconjunctivitis Sicca 0.05% Voclosporin Ophthalmic Solution (VOS), 0.10% VOS | AUPH Aurinia Pharmaceuticals Inc. | Phase 2/3 | Completed | 508 | Sep 17, 2020 | Registry ↗ |
| Sep 16, 2021 | Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental… NCT03598036 · Focal Segmental Glomerulosclerosis Voclosporin | AUPH Aurinia Pharmaceuticals Inc. | Phase 2 | Terminated | 5 | May 19, 2020 | Registry ↗ |
| Jul 8, 2021 | Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Di… NCT03597139 · Dry Eye Voclosporin Ophthalmic Solution, Restasis® | AUPH Aurinia Pharmaceuticals Inc. | Phase 2 | Completed | 100 | Nov 9, 2018 | Registry ↗ |
| May 18, 2021 | AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV) NCT02141672 · Lupus Nephritis Voclosporin High Dose, Voclosporin Low Dose | AUPH Aurinia Pharmaceuticals Inc. | Phase 2 | Completed | 265 | Jul 2016 | Registry ↗ |
| Mar 19, 2021 | Aurinia Early Urinary Protein Reduction Predicts Response NCT02949973 · Lupus Nephritis voclosporin | AUPH Aurinia Pharmaceuticals Inc. | Phase 2 | Completed | 10 | Dec 2016 | Registry ↗ |
| Jan 17, 2018 | Voclosporin in Healthy Japanese Volunteers NCT02949999 · Volunteers Voclosporin | AUPH Aurinia Pharmaceuticals Inc. | Phase 1 | Completed | 40 | Dec 2016 | Registry ↗ |
15 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 9:17 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances